project id: TCGA-BLCA; case submitter id: TCGA-FD-A3B5; no matched normal low pass wgs: false; no matched normal targeted sequencing: false; no matched normal wgs: false; no matched normal wxs: false; selected normal low pass wgs: false; selected normal targeted sequencing: false; selected normal wxs: false; source center: 23; state: released; a260 a280 ratio: 1.79; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.7; rna integrity number: 8.6; age at index: 86; days to birth: -31442; days to death: 272; ethnicity: not hispanic or latino; gender: male; race: black or african american; vital status: Dead; year of birth: 1925; year of death: 2011; age at diagnosis: 31442; ajcc clinical t: T2; ajcc pathologic m: MX; ajcc pathologic n: N1; ajcc pathologic stage: Stage IV; ajcc pathologic t: T2b; ajcc staging system edition: 7th; classification of tumor: not reported; days to diagnosis: 0; icd 10 code: C67.4; last known disease status: not reported; morphology: 8120/3; primary diagnosis: Transitional cell carcinoma; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; site of resection or biopsy: Posterior wall of bladder; synchronous malignancy: No; tissue or organ of origin: Posterior wall of bladder; tumor grade: Not Reported; year of diagnosis: 2011; treatment or therapy: no; alcohol history: Not Reported; cigarettes per day: 1.36986301369863; pack years smoked: 25.0; is ffpe: false; composition: Not Reported; days to collection: 218; days to sample procurement: 0; initial weight: 320.0; portion submitter id: TCGA-FD-A3B5-01A-11; percent lymphocyte infiltration: 2.0; percent monocyte infiltration: 0.0; percent necrosis: 4.0; percent neutrophil infiltration: 1.0; percent normal cells: 0.0; percent stromal cells: 26.0; percent tumor cells: 70.0; percent tumor nuclei: 85.0;